Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Journal of infection and public health ; 2023.
Article in English | EuropePMC | ID: covidwho-2248581

ABSTRACT

Background COVID -19 vaccine can lead to various local and systemic side effects, including menstrual irregularities in women. There is no robust quantitative evidence of the association between the COVID -19 vaccine and menstrual irregularities. A meta-analysis was performed to estimate the pooled prevalence of a range of menstrual disorders that may occur in women following COVID -19 vaccination. Methods After searching for epidemiological studies, we systematically performed a meta-analysis on PubMed/Medline, EMBASE, and Science Direct. Sixteen studies were finally included in the study. We estimated the pooled prevalence and corresponding 95% confidence intervals (CIs) for a group of menstrual disorders, including menorrhagia, polymenorrhea, abnormal cycle length, and oligomenorrhea. Heterogeneity was assessed using the I2 statistic and the Q test. Results Overall, the pooled prevalence of menorrhagia was 24.24% (pooled prevalence 24.24%;95% CI: 12.8-35.6%). The pooled prevalence of polymenorrhea was 16.2% (pooled prevalence: 16.2%;95% CI: 10.7-21.6%). The pooled prevalence of abnormal cycle length was relatively lower than that of the other disorders (pooled prevalence: 6.6%;95% CI: 5.0-8.2%). The pooled prevalence of oligomenorrhea was 22.7% (95% CI: 13.5-32.0%). Conclusion The findings indicate that menorrhagia, oligomenorrhea, and polymenorrhea were the most common menstrual irregularities after vaccination. The findings also suggest that a relatively high proportion of women suffer from menstrual irregularities. Further longitudinal studies are needed to confirm the causal relationship between COVID-19 vaccination and menstrual irregularities.

2.
J Infect Public Health ; 16(5): 697-704, 2023 May.
Article in English | MEDLINE | ID: covidwho-2248582

ABSTRACT

BACKGROUND: COVID - 19 vaccine can lead to various local and systemic side effects, including menstrual irregularities in women. There is no robust quantitative evidence of the association between the COVID - 19 vaccine and menstrual irregularities. A meta-analysis was performed to estimate the pooled prevalence of a range of menstrual disorders that may occur in women following COVID - 19 vaccination. METHODS: After searching for epidemiological studies, we systematically performed a meta-analysis on PubMed/Medline, EMBASE, and Science Direct. Sixteen studies were finally included in the study. We estimated the pooled prevalence and corresponding 95 % confidence intervals (CIs) for a group of menstrual disorders, including menorrhagia, polymenorrhea, abnormal cycle length, and oligomenorrhea. Heterogeneity was assessed using the I2 statistic and the Q test. RESULTS: Overall, the pooled prevalence of menorrhagia was 24.24 % (pooled prevalence 24.24 %; 95 % CI: 12.8-35.6 %). The pooled prevalence of polymenorrhea was 16.2 % (pooled prevalence: 16.2 %; 95 % CI: 10.7-21.6 %). The pooled prevalence of abnormal cycle length was relatively lower than that of the other disorders (pooled prevalence: 6.6 %; 95 % CI: 5.0-8.2 %). The pooled prevalence of oligomenorrhea was 22.7 % (95 % CI: 13.5-32.0 %). CONCLUSION: The findings indicate that menorrhagia, oligomenorrhea, and polymenorrhea were the most common menstrual irregularities after vaccination. The findings also suggest that a relatively high proportion of women suffer from menstrual irregularities. Further longitudinal studies are needed to confirm the causal relationship between COVID-19 vaccination and menstrual irregularities.


Subject(s)
COVID-19 Vaccines , COVID-19 , Menorrhagia , Female , Humans , COVID-19/epidemiology , COVID-19/complications , COVID-19 Vaccines/adverse effects , Menorrhagia/epidemiology , Menorrhagia/complications , Menstruation Disturbances/epidemiology , Menstruation Disturbances/etiology , Oligomenorrhea/complications , Oligomenorrhea/epidemiology , Vaccination/adverse effects
3.
Hum Vaccin Immunother ; 17(10): 3338-3347, 2021 Oct 03.
Article in English | MEDLINE | ID: covidwho-1301323

ABSTRACT

The success of COVID-19 vaccination depends on individual's vaccine acceptance. There has been misinformation on the media that doubts its effectiveness, safety, and long-term risk. Such controversy could affect the acceptance toward the uptake of the COVID-19 vaccine. The objective of this study was to assess the factors influencing the acceptance and hesitancy toward the COVID-19 vaccine in Saudi Arabia. A cross-sectional study was conducted. An online survey was conducted with four parameters: Demographics, medical history, knowledge and information sources about COVID-19 and vaccine, and hesitancy/acceptance of vaccinations. Bivariate analysis between several survey items and the acceptance of COVID-19 vaccine was conducted using Chi-square test. Logistic regression was used to assess to what degree each variable affects the acceptance and the hesitancy toward the COVID-19 vaccine. Approximately 64% show a desire to accept the vaccine while 18.3% were extremely hesitant to take the vaccine. Non-demographic factors that were associated with the acceptance toward the COVID-19 vaccine were the source of health information about COVID-19 (OR:1.63; 95% CI:1.07-2.47), perception toward whether the vaccine is effective on other variants of the virus (OR:7.24; 95% CI:4.58-11.45), previous uptake of the influenza vaccine (OR:1.62; 95% CI:1.07-2.47), and potential mandatory of vaccination in order to travel internationally (OR:16.52; 95% CI:10.23-26.68). This study provides an insight into factors - other than the sociodemographic - influencing the acceptance of the COVID-19 vaccine in Saudi Arabia. The government should address the COVID-19-related misinformation and rumors to increase acceptance of COVID-19 vaccination.


Subject(s)
COVID-19 , Influenza Vaccines , COVID-19 Vaccines , Cross-Sectional Studies , Humans , Internet , SARS-CoV-2 , Saudi Arabia , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL